EYESW (Second Sight Medical Products) YoY EBITDA Growth: 0.00% (As of Jun. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Second Sight Medical Products YoY EBITDA Growth?

Second Sight Medical Products EYESW YoY EBITDA Growth is 0.00% as of Jun. 2022. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Second Sight Medical Products's YoY EBITDA Growth for the quarter that ended in Jun. 2022 was 0.00%.

Second Sight Medical Products's EBITDA per Share for the three months ended in Jun. 2022 was $0.00.

Second Sight Medical Products YoY EBITDA Growth Related Terms

Second Sight Medical Products YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Second Sight Medical Products's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Second Sight Medical Products YoY EBITDA Growth Chart

Second Sight Medical Products Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Second Sight Medical Products Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Second Sight Medical Products YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Second Sight Medical Products's YoY EBITDA Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY EBITDA Growth (A: Dec. 2021 )
=(EBITDA per Share (A: Dec. 2021 )-EBITDA per Share (A: Dec. 2020 ))/ | EBITDA per Share (A: Dec. 2020 ) |
=(-)/ | |
=N/A %

Second Sight Medical Products's YoY EBITDA Growth for the quarter that ended in Jun. 2022 is calculated as:

YoY EBITDA Growth (Q: Jun. 2022 )
=(EBITDA per Share (Q: Jun. 2022 )-EBITDA per Share (Q: Jun. 2021 )) / | EBITDA per Share (Q: Jun. 2021 )) |
=(-)/ | |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 0.00% mean?
Second Sight Medical Products (EYESW) has a YoY EBITDA Growth of 0.00% as of Jun. 2022. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Second Sight Medical Products and its competitors.
Is Second Sight Medical Products' YoY EBITDA Growth too high?
Second Sight Medical Products' current YoY EBITDA Growth is 0.00%.
How does Second Sight Medical Products' YoY EBITDA Growth compare to SONX and LUCD?
Second Sight Medical Products' YoY EBITDA Growth of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Second Sight Medical Products and its competitors. Second Sight Medical Products's current YoY EBITDA Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Second Sight Medical Products stock overvalued right now?
Second Sight Medical Products (EYESW) has a current YoY EBITDA Growth of 0.00%. The current YoY EBITDA Growth is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Second Sight Medical Products (EYESW), the current YoY EBITDA Growth is 0.00% as of Jun. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Second Sight Medical Products Business Description

Address 13170 Telfair Avenue, Sylmar, CA, USA, 91342
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.